ALMR: Revenue grew 68% as FY 2026 guidance rose to $121M–$123M

What happened

Q3 revenue rose 68% year over year to $33.5M, with consumables and instruments both growing strongly. The company raised its full-year 2026 revenue guidance to $121M–$123M, citing large-scale UK Biobank and GSK studies and expanding publications.

Confirmed

Global impact / market context

Faster revenue and a higher guidance range suggest demand for its testing products is strengthening. If consumables keep selling alongside instruments, each new machine can generate repeat revenue, which means future sales may be more predictable.

Analyst inference

Investors often compare a company's guidance with its prior forecast to judge momentum. Raising the revenue range signals management expects more sales, so shareholders may reassess growth, while customers running large studies could shift spending between suppliers.

Analyst inference

What to watch

1. The company cited large-scale UK Biobank and GSK studies as supporting growth prospects, so watch whether these named studies continue and whether they lead to repeat consumable orders. Confirmed
2. Watch whether management raises the $121M–$123M revenue guidance again, which would mean the currently expected sales range is being lifted further. Proposed
3. Track consumables versus instrument sales mix: strong consumables growth can lift profit per sale and cash available, while instrument-led growth may use more cash upfront. Analyst inference

Evidence

• Original source link unavailable